These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30543548)

  • 1. Update on prevention of cytomegalovirus in hematopoietic cell transplantation.
    Dadwal SS
    Curr Opin Infect Dis; 2019 Feb; 32(1):63-68. PubMed ID: 30543548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
    Foolad F; Aitken SL; Chemaly RF
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
    Ljungman P; Schmitt M; Marty FM; Maertens J; Chemaly RF; Kartsonis NA; Butterton JR; Wan H; Teal VL; Sarratt K; Murata Y; Leavitt RY; Badshah C
    Clin Infect Dis; 2020 Apr; 70(8):1525-1533. PubMed ID: 31179485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
    Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
    Transplant Cell Ther; 2024 Aug; 30(8):792.e1-792.e12. PubMed ID: 38838781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
    Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
    Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
    Marty FM; Ljungman PT; Chemaly RF; Wan H; Teal VL; Butterton JR; Yeh WW; Leavitt RY; Badshah CS
    Am J Transplant; 2020 Jun; 20(6):1703-1711. PubMed ID: 31883426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.
    Chemaly RF; El Haddad L; Winston DJ; Rowley SD; Mulane KM; Chandrasekar P; Avery RK; Hari P; Peggs KS; Kumar D; Nath R; Ljungman P; Mossad SB; Dadwal SS; Blanchard T; Shah DP; Jiang Y; Ariza-Heredia E
    Clin Infect Dis; 2020 Dec; 71(9):2365-2374. PubMed ID: 32076709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
    Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
    Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
    Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
    Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
    Alsumali A; Chemaly RF; Graham J; Jiang Y; Merchant S; Miles L; Schelfhout J; Yang J; Tang Y
    J Med Virol; 2021 Jun; 93(6):3786-3794. PubMed ID: 32844453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
    Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
    J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
    P Daukshus N; Cirincione A; Siver M; Mathew S; Kunvarjee B; Chan A; Boelens JJ; Seo SK; Papanicolaou GA; Kernan NA
    J Pediatric Infect Dis Soc; 2022 Jul; 11(7):337-340. PubMed ID: 35472147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.
    Karantoni E; Zavras PD; Su Y; Fang J; Tamari R; Cho C; Perales MA; Stern A; Papanicolaou GA
    Transplant Cell Ther; 2022 Jul; 28(7):403.e1-403.e7. PubMed ID: 35476955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.